Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7752167 | 0.76 | VCAM1 (0.35) | LMNAHTTCYP1A2ALDH1A1TSHR | |
| SCHEMBL7752161 | 0.76 | VCAM1 (0.35) | LMNAHTTCYP1A2ALDH1A1TSHR | |
| SCHEMBL7752158 | 0.75 | VCAM1 (0.32) | LMNACYP1A2ALDH1A1TSHRVCAM1 | |
| SCHEMBL23152122 | 0.74 | ALDH1A1 (0.44) | LMNATP53HTTCYP3A4ALDH1A1 | |
| SCHEMBL5149879 | 0.74 | PDK1 (0.37) | LMNAALDH1A1MAPTSMN1; SMN2PDE2A | |
| SCHEMBL11303709 | 0.73 | ALDH1A1 (0.48) | LMNATP53HTTALDH1A1TSHR | |
| SCHEMBL7878527 | 0.70 | GPR35 (0.44) | TP53CYP3A4ALDH1A1TSHRVCAM1 | |
| SCHEMBL25171482 | 0.70 | PTGER4 (0.41) | LMNATP53HTTALDH1A1TSHR | |
| SCHEMBL27991485 | 0.70 | MCL1 (0.37) | TP53ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL10801476 | 0.69 | TSHR (0.48) | LMNAALDH1A1TSHRVCAM1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617807-A4 | SUBSTITUTED 1,4-DIAZEPINES AND USES THEREOF | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | disclosed |
| CN-1853723-A | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction | ORTHO MCNEIL PHARM INC (US) | 2006-11-01 | — | — | CN | disclosed |
| US-20060235007-A1 | Substituted 1,4-diazepines and uses thereof | LU TIANBAO | 2006-10-19 | — | — | US | disclosed |
| EP-1712235-A2 | Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-7115598-B2 | Substituted 1,4-diazepines and uses thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| CN-1809362-A | Substituted 1,4-diazepines and uses thereof | JOHNSON & JOHNSON (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1617807-A2 | SUBSTITUTED 1,4-DIAZEPINES AND USES THEREOF | Ortho-McNeil Pharmaceuticals, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050227932-A1 | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2004096134-A2 | SUBSTITUTED 1,4-DIAZEPINES AND USES THEREOF | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220179-A1 | Substituted 1,4-diazepines and uses thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235007-A1 | Substituted 1,4-diazepines and uses thereof | MDM2, TP53, RB1 | LMNA 3920/4885TP53 2/4885HTT 400/4885 |
| US-20050227932-A1 | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction | TP53, MDM2, TP53BP1 | LMNA 3794/4885TP53 1/4885HTT 1312/4885 |
| US-20040220179-A1 | Substituted 1,4-diazepines and uses thereof | TP53, MDM2, HRH2 | LMNA 3185/4885TP53 1/4885HTT 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.